Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.98 +1.28%

+$0.16 today

Market cap
$150.57M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.23M

Average 0.35M

Returns on capital

Atrium Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-37.0%

avg -37.0%

ROIC

-31.9%

avg -31.9%

ROA

-27.5%

avg -27.5%

Analysis

ROA is currently the strongest return metric at -27.5% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Husam Younis

Chief Scientific Officer—5241.44K0.24%

Brendan Winslow

Chief Financial Officer—38——

Steven George Hughes

Chief Medical Officer—5951.64K0.30%

Kathleen Gallagher

President, CEO & Director—45——

Rocio Martin Hoyos

Chief Strategy Officer—4338.34K0.22%

Stephanie Kenney

Chief Corporate Affairs Officer—4833.09K0.19%

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+0.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +0.0% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Atrium Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Questions

Management questions

Common questions about RNA's management, answered from reported figures.

Who manages RNA?

Atrium Therapeutics, Inc. (RNA) lists 6 active executives. The top listed executive is Husam Younis, Chief Scientific Officer.

Are RNA insiders buying or selling?

Recent insider activity shows net selling of $1.89M.